Cullinan Therapeutics, Inc.CGEMEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted oncology therapies to address unmet medical needs for patients with hard-to-treat cancers. Its core pipeline includes candidates for solid tumors and hematological malignancies, with operations and R&D partnerships spanning North America and global oncology research networks.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Franklin Resources, Inc. | 7.70% | 3.3M | — | 2024-02-06 |
| BlackRock, Inc. | 7.50% | 4.3M | flat | 2024-11-08 |
| OF ABOVE PERSONS | 5.71% | 3.3M | — | 2024-04-24 |
| Biotechnology Value Fund, L.P. | 5.20% | 3.0M | ▼ -1.30pp | 2024-11-14 |
| The Vanguard Group | 5.17% | 3.0M | flat | 2024-11-12 |
| Blue Owl Capital Holdings LP | 3.45% | 2.0M | ▼ -4.54pp | 2024-11-14 |
| Globeways | 1.10% | 468.7K | — | 2024-02-14 |
Insider Transactions
Net 90d: −$541.2K · buys $0 / sells $541.2KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-05 | Jennifer Michaelson | Chief Scientific Officer | Option exercise | 4.0K | $4.30 | $17.2K |
| 2026-03-05 | Jennifer Michaelson | Chief Scientific Officer | Sell (open market) | 8.0K | $15.68 | $125.4K |
| 2026-02-25 | Jennifer Michaelson | Chief Scientific Officer | Sell (open market) | 1.8K | $14.14 | $25.2K |
| 2026-02-24 | Jones Jeffrey Alan | Chief Medical Officer | Sell (open market) | 4.6K | $14.47 | $66.3K |
| 2026-02-24 | SUMER JACQUELYN L | Chief Legal Officer | Sell (open market) | 3.6K | $14.47 | $52.1K |
| 2026-02-24 | Jennifer Michaelson | Chief Scientific Officer | Sell (open market) | 3.6K | $14.47 | $52.1K |
| 2026-02-24 | AHMED NADIM | President and CEO | Sell (open market) | 13.5K | $14.47 | $195.6K |
| 2026-02-23 | Jennifer Michaelson | Chief Scientific Officer | Sell (open market) | 1.8K | $13.99 | $24.5K |
1–8 of 8